AJP - GI AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol (April 23, 2009). doi:10.1152/ajpgi.00045.2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
297/1/G98    most recent
00045.2009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herath, C. B
Right arrow Articles by W Angus, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herath, C. B
Right arrow Articles by W Angus, P.
Submitted on February 4, 2009
Revised on April 3, 2009
Accepted on April 15, 2009

Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of angiotensin converting enzyme (ACE) and ACE2

Chandana B Herath1*, John S Lubel2, Zhiyuan Jia1, Elena Velkoska1, David Casley1, Lindsay Brown3, Chris Tikellis4, Louise M Burrell1, and Peter W Angus5

1 University of Melbourne
2 Austin Hospital
3 The University of Queensland
4 Baker Heart Research Institute
5 Austin Health

* To whom correspondence should be addressed. E-mail: cherath{at}unimelb.edu.au.

Angiotensin converting enzyme (ACE) 2 activity and angiotensin-(1-7) [Ang-(1-7)] levels are increased in experimental cirrhosis, however the pathways of hepatic Ang-(1-7) production have not been studied. This study investigated the role of ACE2, ACE and neutral endopeptidase (NEP) in the hepatic formation of Ang-(1-7) from angiotensin I (Ang I) and Ang II and their effects on portal resistance. Ang I or Ang II were administered to rat bile duct ligated (BDL) and control livers alone and in combination with the ACE inhibitor lisinopril, ACE and NEP inhibitor omapatrilat or the ACE2 inhibitor MLN4760 (n=5 per group). BDL markedly upregulated ACE, ACE2 and NEP. Ang-(1-7) was produced from Ang II in healthy and in BDL livers and was increased following ACE inhibition and decreased by ACE2 inhibition. In contrast, Ang-(1-7) production from Ang I was minimal and not affected by ACE or NEP inhibition. Surprisingly, ACE2 inhibition in BDLs dramatically increased Ang-(1-7) production from Ang I, an effect abolished by ACE2/NEP inhibition. Ang II and Ang I induced greater portal pressure increases in BDL livers than controls. The effects of Ang I were closely correlated with Ang II production and were strongly attenuated by both ACE and ACE/NEP inhibition. These findings show that the major substrate for hepatic production of Ang-(1-7) is Ang II and this is catalysed by ACE2. Ang I is largely converted to Ang II by ACE, and net conversion of Ang I to Ang-(1-7) is small. NEP has the ability to generate large amounts of Ang-(1-7) in the BDL liver from Ang I only when ACE2 activity is greatly decreased or inhibited.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.